In recent years, MET/HGF inhibition has emerged as a promising anticancer therapy option since aberrant MET/HGF activation, which occurs via a myriad of mechanisms and oncogenic receptor pathways, has largely been linked with several aggressive cancer phenotypes, increased metastasis, and poor prognosis.20 This evidence concerns the gene HGF and cancer.